Compare Newmont Corporation (NEM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Organon & Co. Common Stock — how do they compare? Newmont Corporation trades at $113 (market cap $117.55B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Newmont Corporation is far larger — about 32.6× Organon & Co. Common Stock's market cap, and Newmont Corporation pays the higher dividend (0.93%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Organon & Co. Common Stock for 0 Days on average.
| NEM | OGN | |
|---|---|---|
Market Cap | $117.55B | $3.61B |
Volume | 6,644,300 | 1,808,049 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $13.81 |
52-Week Low | $78.63 | $5.70 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.14B | $11.03B |
Dividend Yield | 0.93% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $115.59, down 1.33% on the day, as the gold mining giant demonstrates strong fundamental performance with record revenue of $22.67 billion in 2025 and net income of $7.09 billion. The stock shows a bullish technical trend with support at $115 and resistance at $118, while maintaining attractive valuation metrics including a P/E of 14.58 and ROE of 25.53%. Recent news highlights the company's record $5.3 billion free cash flow and focus on per-share growth through operational improvements.
Newmont presents a compelling investment case with strong analyst support (76% buy ratings) and a $136.83 consensus price target representing 18% upside. The company's transformation from losses in 2022-2023 to robust profitability, coupled with disciplined capital allocation and gold price tailwinds, supports continued growth. Key risks include gold price volatility, operational execution challenges, and broader market conditions that could pressure mining stocks despite strong fundamentals.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
